Repligen Corporation $RGEN Shares Bought by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC raised its position in Repligen Corporation (NASDAQ:RGEN) by 20.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 435,687 shares of the biotechnology company’s stock after acquiring an additional 73,558 shares during the quarter. TimesSquare Capital Management LLC owned 0.77% of Repligen worth $71,392,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in RGEN. AQR Capital Management LLC acquired a new stake in shares of Repligen during the first quarter worth approximately $262,000. Jones Financial Companies Lllp grew its position in shares of Repligen by 3,850.6% during the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after buying an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock worth $18,067,000 after buying an additional 20,375 shares in the last quarter. Bank of Nova Scotia grew its position in shares of Repligen by 88.0% during the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock worth $3,951,000 after buying an additional 14,860 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its position in shares of Repligen by 29.7% during the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after buying an additional 7,148 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Rothschild & Co Redburn set a $160.00 price target on shares of Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Canaccord Genuity Group decreased their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 7th. Jefferies Financial Group reissued a “hold” rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. Finally, Roth Mkm assumed coverage on shares of Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $166.15.

Repligen Stock Performance

Shares of RGEN opened at $104.20 on Tuesday. The business’s fifty day moving average price is $118.54 and its 200 day moving average price is $141.71. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $175.77. The stock has a market capitalization of $5.88 billion, a PE ratio of 115.78, a price-to-earnings-growth ratio of 1.98 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.26 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same period last year, the business posted $0.39 earnings per share. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts forecast that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.